linkurl:Elizabeth Nabel,;http://www.nhlbi.nih.gov/about/director.htm the director of the National Institutes of Health's National Heart Lung and Blood Institute (NHLBI) will be leaving her post on January 1, 2010 to take a position as president and CEO of Brigham and Women's/Faulkner Hospitals in Boston, according to internal NIH emails.
Nabel, a cardiologist by training, joined NHLBI 10 years ago as the institute's scientific director of clinical research. She took over the top spot at the institute in 2005. Nabel's research addresses genetic and cellular therapies for cardiovascular disease, and her NHLBI lab linkurl:identified;http://www.ncbi.nlm.nih.gov/pubmed/12093740?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum p27, a cyclin-dependent kinase inhibitor, as a major regulator of vascular cell proliferation during arterial remodeling. Earlier this year, Nabel's name was bandied about as a possible candidate for the post of NIH director, ultimately filled by Francis Collins. "Over the next few weeks, I will be working with Drs. Collins and [Raynard] Kington [NIH's deputy...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?